VRTX — Vertex Pharmaceuticals Inc · P/E 30, rev $3.33B

Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..

Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.

Use this VRTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VRTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VRTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Vertex Pharmaceuticals Inc even when a live quote feed is slow.